Please assess the completion status of the following clinical trial:

Trial Title: Trental for the Treatment of Vertigo/Dizziness/Imbalance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults 40 years and older~2. English as primary language~3. Diagnosis of multisensory losses, presbystasis, bilateral vestibulopathy, central vascular insufficiency, small vessel circulatory disease, generalized imbalance, and idiopathic peripheral vertigo scoring at least 16 on the Dizziness Handicap Inventory~4. Willingness to complete surveys and take medication as prescribed~Exclusion Criteria:~1. Diagnosis of the following: benign paroxysmal positional vertigo, Meniere's disease, vestibular migraine with headache, intracranial mass, perilymphatic fistula, or multiple sclerosis~2. history of cholesteatoma~3. Prior ear surgery other than myringotomy and tube placement~4. Prior radiation to head or neck~5. previous use of vestibulotoxic medications where the enrolling provider determines the drug exposure to be the cause of imbalance~6. Use of blood thinning medications~7. intolerance/allergy to pentoxifylline or methylxanthines, as well as recent cerebral or retinal hemorrhage (past 3 months)~8. Pregnant or lactating females.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pentoxifylline (Type: EXPERIMENTAL): Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Patients will take placebo 3 times per day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).